Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| 4.86 | |
| 4.8 | |
| - | |
| 4.86 | |
| 4.8 | |
| 4.38-8.56 | |
| 147 M | |
| 21 584 K | |
| 5 854 K | |
| -0.08 | |
| 0.63 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Outlook Therapeutics, Inc. Live webcast fireside chat on Monday, August 7th at 1:00 PM ET ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceuti...
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Outlook Therapeutics, Inc., a late clinical-s...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
